Is Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) P/E Ratio Really That Good?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We’ll show how you can use Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) P/E ratio to inform your assessment of the investment opportunity. Eagle Pharmaceuticals has a price to earnings ratio of 22.72, based on the last twelve months. In other words, at today’s prices, investors are paying $22.72 for every $1 in prior year profit.

Check out our latest analysis for Eagle Pharmaceuticals

How Do You Calculate A P/E Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Or for Eagle Pharmaceuticals:

P/E of 22.72 = $49.07 ÷ $2.16 (Based on the trailing twelve months to December 2018.)

Is A High Price-to-Earnings Ratio Good?

A higher P/E ratio means that buyers have to pay a higher price for each $1 the company has earned over the last year. That is not a good or a bad thing per se, but a high P/E does imply buyers are optimistic about the future.

How Growth Rates Impact P/E Ratios

P/E ratios primarily reflect market expectations around earnings growth rates. When earnings grow, the ‘E’ increases, over time. That means unless the share price increases, the P/E will reduce in a few years. So while a stock may look expensive based on past earnings, it could be cheap based on future earnings.

Eagle Pharmaceuticals’s earnings per share fell by 37% in the last twelve months. But it has grown its earnings per share by 58% per year over the last five years.

How Does Eagle Pharmaceuticals’s P/E Ratio Compare To Its Peers?

The P/E ratio indicates whether the market has higher or lower expectations of a company. You can see in the image below that the average P/E (22.9) for companies in the biotechs industry is roughly the same as Eagle Pharmaceuticals’s P/E.

NasdaqGM:EGRX Price Estimation Relative to Market, March 5th 2019
NasdaqGM:EGRX Price Estimation Relative to Market, March 5th 2019

Its P/E ratio suggests that Eagle Pharmaceuticals shareholders think that in the future it will perform about the same as other companies in its industry classification. If the company has better than average prospects, then the market might be underestimating it. Checking factors such as the tenure of the board and management could help you form your own view on if that will happen.

Don’t Forget: The P/E Does Not Account For Debt or Bank Deposits

Don’t forget that the P/E ratio considers market capitalization. Thus, the metric does not reflect cash or debt held by the company. Hypothetically, a company could reduce its future P/E ratio by spending its cash (or taking on debt) to achieve higher earnings.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

Eagle Pharmaceuticals’s Balance Sheet

Eagle Pharmaceuticals has net cash of US$34m. That should lead to a higher P/E than if it did have debt, because its strong balance sheets gives it more options.

The Bottom Line On Eagle Pharmaceuticals’s P/E Ratio

Eagle Pharmaceuticals has a P/E of 22.7. That’s higher than the average in the US market, which is 17.7. The recent drop in earnings per share would make some investors cautious, but the relatively strong balance sheet will allow the company time to invest in growth. Clearly, the high P/E indicates shareholders think it will!

When the market is wrong about a stock, it gives savvy investors an opportunity. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

You might be able to find a better buy than Eagle Pharmaceuticals. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.